Insiders Allogene Therapeutics, Inc.

Equities

ALLO

US0197701065

Market Closed - Nasdaq Other stock markets 01:30:00 22/06/2024 am IST			5-day change	1st Jan Change
2.55 ^USD	+4.51%		+8.51%	-20.56%

20/06	Allogene Therapeutics Inc. Initiates Pivotal Phase 2 Trial Investigating Cemacabtagene Ansegedleucel as Part of First Line Treatment for Patients with Large B-Cell Lymphoma	CI
10/06	Allogene Therapeutics, Inc. Announces Executive Changes	CI

Insiders

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Allogene Therapeutics, Inc. Announces Executive Changes	11/06	CI
Allogene Therapeutics, Inc. Appoints Geoffrey Parker as Executive Vice President	16/23/16	CI
Allogene Therapeutics Finance Chief Eric Schmidt to Step Down	14/23/14	MT
Allogene Therapeutics, Inc. Announces Resignation of Eric Schmidt from Principal Financial Officer and Principal Accounting Officer, Effective from August 2, 2023	14/23/14	CI
Allogene Therapeutics, Inc. Appoints Timothy Moore as Executive Vice President and Chief Technical Officer, Effective April 24, 2023	21/23/21	CI
Allogene Therapeutics, Inc., Announces Resignation of Alison Moore as Chief Technical Officer, Effective April 28, 2023	21/23/21	CI
Allogene Therapeutics, Inc. Announces Resignation of Rafael G. Amado as Executive Vice President of Research and Development	03/23/03	CI
Allogene Appoints Zachary J. Roberts as Executive Vice President of Research & Development	03/23/03	CI
Insider Sell: Allogene Therapeutics	16/22/16	MT
Allogene Therapeutics, Inc. Appoints Scientific Pioneer Stephen Mayo to its Board of Directors	12/22/12	CI
Insider Sell: Allogene Therapeutics	24/22/24	MT
Allogene Therapeutics, Inc. Appoints Susan Lundeen as Chief People Officer, Effective May 2, 2022	28/22/28	CI
Insider Buy: Allogene Therapeutics	15/22/15	MT
Insider Buy: Allogene Therapeutics	14/22/14	MT
Allogene Therapeutics Appoints Jae Park to Its Scientific Advisory Board	20/21/20	CI
Insider Sell: Allogene Therapeutics	18/21/18	MT
Insider Sell: Allogene Therapeutics	10/21/10	MT
Allogene Therapeutics, Inc. Announces Executive Appointments	02/21/02	CI
Allogene Overland Biopharm, a Joint Venture Created by Overland Pharmaceuticals and Allogene Therapeutics, Inc. Appoints Shuyuan Yao as Chief Executive Officer	21/21/21	CI
Gracell Biotechnologies : Names Jenny Ni Chief Technology Officer	11/21/11	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Insiders Allogene Therapeutics, Inc.

Equities

ALLO

US0197701065

Insiders

Filters